Product image of Kabazitaksel Sandoz (Cabazitaxel) supplied by GNH India

Kabazitaksel Sandoz

Active Ingredient:
Cabazitaxel
Origin:
EU

Kabazitaksel Sandoz (Cabazitaxel)

Cabazitaxel, the active ingredient in Kabazitaksel Sandoz, is a Taxane presented as a solution for injection for intravenous use. It treats metastatic castration‑resistant prostate cancer after prior docetaxel therapy in patients with disease progression. The drug belongs to the taxane class of antineoplastic agents and works by disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis of cancer cells.

GNH India supplies Kabazitaksel Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide with consistent quality and regulatory compliance.

Manufacturer / TM Owner

Sandoz D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Cabazitaxel is a taxane chemotherapy used in the treatment pathway for advanced prostate cancer.

  • Metastatic castration‑resistant prostate cancer after docetaxel: provides an additional line of therapy to improve overall survival.
  • Prostate cancer with progression despite androgen‑deprivation therapy: offers a chemotherapy option when hormonal treatment fails.
  • Advanced prostate cancer not responding to prior taxane chemotherapy: delivers an alternative mechanism of action for disease control.

How It Works

  • Cabazitaxel binds to the β‑tubulin subunit of microtubules, promoting polymerization and stabilizing the microtubule network. This prevents depolymerization, disrupts mitotic spindle formation, arrests cells in the G2/M phase, and triggers apoptosis in rapidly dividing cancer cells, particularly those resistant to other taxanes.

Side Effects

Cabazitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Fatigue: persistent tiredness affecting daily activities.
  • Anemia: lowered red blood cell levels causing weakness.
  • Nausea: upset stomach often accompanied by vomiting.
  • Diarrhea: loose stools that may lead to dehydration.
  • Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

  • Febrile neutropenia: fever with low neutrophils requiring urgent care.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Cardiac toxicity: arrhythmias or decreased heart function.
  • Pulmonary embolism: blood clot in the lungs presenting with sudden breathlessness.
  • Life‑threatening infections: sepsis due to immunosuppression.
  • Death: rare but possible in cases of severe toxicity.

Precautions & Warnings

Before initiating Cabazitaxel therapy, clinicians should assess patient suitability and monitor for potential complications.

  • Monitor blood counts: perform regular CBC to detect neutropenia and anemia.
  • Assess hepatic function: check liver enzymes as cabazitaxel is metabolized hepatically.
  • Evaluate for hypersensitivity: observe for infusion‑related reactions during administration.
  • Avoid use in patients with active severe infection: risk of worsening infection due to myelosuppression.
  • Use caution in elderly or frail patients: increased susceptibility to toxicity.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Cabazitaxel can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure and toxicity.
  • Concurrent myelosuppressive agents: heighten risk of severe neutropenia and anemia.
  • Live vaccines: immunosuppression can reduce vaccine effectiveness and increase infection risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower cabazitaxel levels, reducing effectiveness.
  • Anticoagulants (e.g., warfarin, DOACs): increased bleeding risk due to platelet effects.
  • Diuretics: potential for electrolyte disturbances when combined with fluid shifts during infusion.

Frequently Asked Questions

Kabazitaksel Sandoz contains cabazitaxel, a taxane chemotherapy indicated for the treatment of metastatic castration‑resistant prostate cancer in patients whose disease has progressed after prior docetaxel therapy. It provides an additional line of systemic therapy aimed at extending survival.

Cabazitaxel binds to β‑tubulin, stabilizing microtubules and preventing their depolymerization. This interferes with mitotic spindle formation, arrests cancer cells in the G2/M phase of the cell cycle, and ultimately triggers programmed cell death (apoptosis) in rapidly dividing tumor cells.

The specific dose and schedule of Kabazitaksel Sandoz are determined by the prescribing oncologist based on the patient’s clinical condition, prior therapies, and laboratory parameters. The prescriber will calculate the appropriate amount for each infusion.

The safety of cabazitaxel in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential harm to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period afterward.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Cabazitaxel is a next‑generation taxane designed to retain activity in tumors that have become resistant to earlier taxanes such as docetaxel. It shows improved binding to tubulin and reduced susceptibility to common resistance mechanisms, offering an alternative when disease progresses after first‑line taxane therapy.

Kabazitaksel Sandoz should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original container until ready for preparation and administration to maintain stability.

The medication is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. Infusion rates and pre‑medication protocols are determined by the treating physician to minimize infusion‑related reactions.

The most serious adverse events include febrile neutropenia, severe infections, life‑threatening allergic reactions, cardiac toxicity, and pulmonary embolism. Patients should be closely monitored for signs of infection, respiratory distress, and cardiovascular changes throughout treatment.

Kabazitaksel Sandoz is contraindicated in patients with known hypersensitivity to cabazitaxel or any component of the formulation, in those with active severe infections, and in individuals who are pregnant or breastfeeding. Caution is also advised for patients with significant hepatic impairment or uncontrolled cardiac disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cabazitaxel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT